Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome – still an open question?

References

• Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007;67:1567–1601.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133–163.
   PubMed Web of Science ®Google Scholar
• Morris A, Lundgren JD, Masur H, et al Current epidemiology of Pneumocystis pneumonia. Emerging Infect Dis 2004;10:1713–1720.
   PubMed Web of Science ®Google Scholar
• Vehreschild J, Rüping MJGT, Cornely O. Fungiscope – A Global Rare Fungal Infection Registry. 2006 [cited; Available from: www.fungiscope.net].
   Google Scholar
• Maertens J, Theunissen K, Verhoef G, et al Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242–1250.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Picardi M, et al Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality – SEIFEM-C Report. Clin Infect Dis 2007; 44:1524–1525.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289–1297.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Ribaud P, Herbrecht R, et al Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006;42:955–963.
   PubMed Web of Science ®Google Scholar
• Martino R, Subira M, Rovira M, et al Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116:475–482.
   PubMed Web of Science ®Google Scholar
• Greene RE, Schlamm HT, Oestmann JW, et al Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373–379.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764–771.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, et al Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391–1402.
   PubMed Web of Science ®Google Scholar
• Leon C, Ruiz-Santana S, Saavedra P, et al A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006;34:730–737.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348–359.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335–347.
   PubMed Web of Science ®Google Scholar
• Rüping MJGT, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 2008;68:1941–1962.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Böhme A, Buchheidt D, et al Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009;94:113–122.
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA, et al A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Eng J Med 1992;326:845–851.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R, et al Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545–1552.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH, et al Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705–713.
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W, et al Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527–1533.
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Cornely O, Ullmann AJ, et al An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006;57:317–325.
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Prentice A. Current experience with itraconazole in neutropenic patients: a concise overview of pharmacological properties and use in prophylactic and empirical antifungal therapy. Clin Microbiol Infect 2006;12(Suppl 7):84–90.
   PubMed Web of Science ®Google Scholar
• Farowski F, Vehreschild JJ, Cornely OA. Posaconazole: a next-generation triazole antifungal. Future Microbiol 2007;2:231–243.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Bohme A, Buchheidt D, et al A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007;55:445–449.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Stollorz A, Beisel C, Karthaus M, Vehreschild J. Impact of posaconazole prophylaxis on the epidemiology of invasive aspergillosis. 47th interscience conference on antimicrobial agents and chemotherapy; Chicago; 2007.
   Google Scholar
• Mattiuzzi GN, Alvarado G, Kantarjian HM. Intravenous Voriconazole (IV-VORI) prevents invasive fungal infections (IFI) in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). 46th American society of hematology annual meeting; San Diego; 2004.
   Google Scholar
• Mattiuzzi GN, Alvarado G, Giles FJ, et al Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006;50:143–147.
   PubMed Web of Science ®Google Scholar
• Klastersky J. Empirical antifungal therapy. Int J Antimicrob Agents 2004;23:105–112.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225–234.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Heussel CP, Cornely OA. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Eng J Med 2002;346:1745–1747; discussion 7.
   PubMed Web of Science ®Google Scholar
• Marr KA. Empirical antifungal therapy – new options, new tradeoffs. N Engl J Med 2002;346:278–280.
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Selleslag D, et al Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005;41:e9–e14.
   PubMed Web of Science ®Google Scholar
• Lin MT, Lu HC, Chen WL. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis 2001;33:1621–1627.
   PubMed Web of Science ®Google Scholar
• White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006;42:479–486.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Link H, Böhme A, Cornely OA, et al Antimicrobial therapy of unexplained fever in neutropenic patients. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82(Suppl 2):S105–S117.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, et al Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042–1051.
   PubMed Web of Science ®Google Scholar
• Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 2008: CD007394.
   PubMed Web of Science ®Google Scholar
• Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762–1769.
   PubMed Web of Science ®Google Scholar
• Orlopp K, von Lilienfeld-Toal M, Marklein G, et al False positivity of the Aspergillus galactomannan Platelia ELISA because of piperacillin/tazobactam treatment: does it represent a clinical problem? J Antimicrob Chemother 2008;62:1109–1112.
   PubMed Web of Science ®Google Scholar
• De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis – has the principle been proven? N Engl J Med 2007;356:409–411.
   PubMed Web of Science ®Google Scholar
• Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007;51:1897–1904.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274–1277.
   PubMed Web of Science ®Google Scholar
• Weiler S, Lass-Florl C, Auberger J, et al Triazole-resistant candidaemia following posaconazole exposure. Int J Antimicrob Agents 2009;33:494–495.
   PubMed Web of Science ®Google Scholar
• Snelders E, Huis In 't Veld RA, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 2009;75:4053–4057.
   PubMed Web of Science ®Google Scholar
• Hof H. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist Update 2008;11:25–31.
   PubMed Web of Science ®Google Scholar
• Collins CD, Ellis JJ, Kaul DR. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 2008;65:2237–2243.
   PubMed Web of Science ®Google Scholar
• Stam WB, O'Sullivan AK, Rijnders B, et al Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 2008;81:467–474.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Ullmann AJ. Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis 2008;46:1626–1627; author reply 7–8.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.
   PubMed Web of Science ®Google Scholar